FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Zacks·1d ago
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.
Zacks·1d ago
Viatris Stock to Report Q4 Earnings: What's in the Cards?
VTRS gears up for Q4 results amid Indore import alert, segment revenue pressure and steady margins as shares surge 39.7% in a year.
Zacks·1d ago
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View
INSM shares jump 7% as Brinsupri sales surge and 2026 outlook calls for at least $1B, despite a wider Q4 loss and rising expenses.
Zacks·4d ago
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Zacks·4d ago
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 7% - Should You Sell?
Castle Biosciences (NASDAQ:CSTL) Trading Down 7% - Should You Sell...
MarketBeat·5d ago
BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth
Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.
Zacks·5d ago
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Castle Biosciences (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?
COLL gears up to report Q4 earnings. Strong Jornay PM demand and higher pain portfolio sales fuel investor expectations ahead of its Feb. 26 report.